Prelude Therapeutics Incorporated
NASDAQ Global SelectTotal Valuation
Prelude Therapeutics Incorporated carries a market capitalization of 206.63M, placing it among publicly traded companies globally. Its enterprise value stands at 291.00M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 206.63M |
| Enterprise Value | 291.00M |
Share Statistics
Prelude Therapeutics Incorporated currently has 79.76M shares outstanding.
| Shares Outstanding | 79.76M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 20.37, and the price-to-book ratio stands at 3.18.
| PE Ratio | N/A |
| PS Ratio | 20.37 |
| PB Ratio | 3.18 |
| P/TBV Ratio | 3.18 |
| P/FCF Ratio | -13.73 |
| P/OCF Ratio | -13.73 |
Enterprise Valuation
| EV / Sales | 12.98 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Prelude Therapeutics Incorporated maintains a current ratio of 4.07, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.07 |
| Quick Ratio | 3.99 |
| Debt / Equity | 13.20 |
| Debt / EBITDA | -0.27 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -57.73 |
| Return on Assets (ROA) | -39.76 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Prelude Therapeutics Incorporated's stock has gained approximately 176.74419% over the past 52 weeks. The 50-day moving average sits at 4.78, while the 200-day moving average is 3.95.
| Beta (5Y) | N/A |
| 52-Week Price Change | 176.74419% |
| 50-Day Moving Average | 4.78 |
| 200-Day Moving Average | 3.95 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Prelude Therapeutics Incorporated generated 22.42M in revenue and converted that into -60.49M in net income, yielding earnings per share of -0.71. EBITDA reached -65.81M, while operating income came in at -67.40M.
| Revenue | 22.42M |
| Gross Profit | N/A |
| Operating Income | -67.40M |
| Pretax Income | -60.49M |
| Net Income | -60.49M |
| EBITDA | -65.81M |
| EBIT | -67.40M |
| Earnings Per Share (EPS) | -0.71 |
Balance Sheet
Prelude Therapeutics Incorporated holds 151.76M in cash and equivalents against 17.65M in total debt, resulting in a net debt position of -26.33M. Total book value stands at 133.73M, with working capital of 116.86M providing operational flexibility.
| Cash & Cash Equivalents | 151.76M |
| Total Debt | 17.65M |
| Net Debt | -26.33M |
| Equity (Book Value) | 133.73M |
| Book Value Per Share | 1.68 |
| Working Capital | 116.86M |
Cash Flow
Prelude Therapeutics Incorporated produced -33.25M in operating cash flow over the past twelve months.
| Operating Cash Flow | -33.25M |
| Capital Expenditures | N/A |
| Free Cash Flow | -33.25M |
| FCF Per Share | -0.39 |
Margins
Prelude Therapeutics Incorporated operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -300.56 and net profit margin of -269.75 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -300.56 |
| Pretax Margin | -269.75 |
| Profit Margin | -269.75 |
| EBITDA Margin | -293.48 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -25.98 |
| FCF Yield | -7.28 |
Scores
Prelude Therapeutics Incorporated posts an Altman Z-Score of -0.96, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.96 |